CBX-250 / Crossbow Therap - LARVOL DELTA

CROSSCHECK-001: A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Crossbow Therapeutics, Inc.

New P1 trial • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo (ASH 2024) - "Significantly, CBX-250 does not induce T cell activation or IFNg production when co-cultured with HLA-A2 positive healthy donor (HD) neutrophils and displays no toxicity towards normal hematopoietic stem cells (HSC) and progenitor cells in a colony forming unit (CFU) assay, in contrast to a cytarabine-treated positive control. Taken together, these data provide strong preclinical evidence of the potency, specificity, and safety of CBX-250 against a novel tumor antigen that may provide a wider therapeutic index relative to other well characterized AML targets. These findings support further development in the clinic and IND-enabling studies for CBX-250 are currently ongoing."

IO biomarker • Preclinical • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Targeted Protein Degradation • CBX2 • CD123 • CD14 • CD33 • CD34 • CTSG • DNMT3A • FLT3 • HLA-A • IFNG • IL3RA • NPM1

Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia (AACR 2024) - "Finally, the CBX-250 precursor molecule demonstrated favorable safety in a double transgenic mouse model expressing human HLA-A2 and CG1.Following sequence optimization, CBX-250 demonstrated robust serum and pH stress stability and a favorable melting temperature, while retaining excellent potency and specificity. A full suite of analytical and biophysical assessments supports CBX-250's favorable developability profile.In summary, these data provide strong preclinical evidence of the potency, specificity, safety, and developability of CBX-250, a novel, first-in-class, off-the-shelf, TCRm-based TCE for the treatment of myeloid malignancies."

Hematological Malignancies • Leukemia • Oncology • CTSG • HLA-A • IFNG

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets (GlobeNewswire) - "Crossbow Therapeutics, Inc...today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia....The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex."

Preclinical • Hematological Malignancies • Leukemia • Oncology